(Q35163589)

6 August 2017

1 reference

title

Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure (English)

1 reference

6 August 2017

Current Status of Phosphodiesterase Inhibitors in the Treatment of Congestive Heart Failure (English)

1 reference

10.2165/00003495-199244060-00003

Crossref

DOI

https://api.crossref.org/works/10.2165/00003495-199244060-00003

22 November 2023

main subject

congestive heart failure

1 reference

T. A. Fischer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1282864

22 November 2023

R. Erbel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1282864

22 November 2023

N. Treese

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1282864

22 November 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1282864

22 November 2023

publication date

1 December 1992

1 reference

6 August 2017

1 reference

6 August 2017

44

1 reference

6 August 2017

6

1 reference

6 August 2017

928-945

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199244060-00003

6 August 2017

0 references

cites work

Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure

1 reference

12 December 2020

Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

1 reference

12 December 2020

Regulation of cardiac L-type calcium current by phosphorylation and G proteins

1 reference

12 December 2020

[Effect of oral long-term enoximone therapy on the arrhythmia profile in chronic heart failure]

1 reference

12 December 2020

The effect of troponin I phosphorylation on the Ca2+-binding properties of the Ca2+-regulatory site of bovine cardiac troponin

1 reference

12 December 2020

Effects of the phosphodiesterase III inhibitor in ischemic heart disease

1 reference

12 December 2020

Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance

1 reference

12 December 2020

Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside

1 reference

12 December 2020

Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure

1 reference

12 December 2020

Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Phosphodiesterase-inhibiting properties of newer inotropic agents

1 reference

12 December 2020

A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure

1 reference

12 December 2020

Electrophysiologic effects of milrinone in patients with congestive heart failure.

1 reference

12 December 2020

Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Amrinone in the treatment of chronic cardiac failure

1 reference

12 December 2020

The cellular basis of contraction and relaxation in cardiac and vascular smooth muscle

1 reference

12 December 2020

A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity

1 reference

12 December 2020

Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts

1 reference

12 December 2020

Effects of milrinone on left ventricular remodeling after acute myocardial infarction

1 reference

12 December 2020

Hemodynamic and clinical evaluation of piroximone, a new inotrope-vasodilator agent, in severe congestive heart failure

1 reference

12 December 2020

Long-term therapy of chronic cardiac insufficiency using enoximone

1 reference

12 December 2020

Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure

1 reference

12 December 2020

Chronic therapy of severe heart failure with enoximone

1 reference

12 December 2020

Hemodynamic, antiischemic, and neurohumoral effects of enoximone in patients with coronary artery disease.

1 reference

12 December 2020

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

1 reference

12 December 2020

Electrophysiological effects of intravenous MDL 17.043

1 reference

12 December 2020

The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy man

1 reference

12 December 2020

Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group

1 reference

12 December 2020

Acute hemodynamic effects of piroximone (MDL 19,205) in patients with moderate congestive heart failure: comparison with sodium nitroprusside.

1 reference

12 December 2020

Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents

1 reference

12 December 2020

Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.

1 reference

12 December 2020

Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone

1 reference

12 December 2020

Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure

1 reference

12 December 2020

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

12 December 2020

Cyclic adenosine monophosphate effects on the myocardium: A man who blows hot and cold with one breath

1 reference

12 December 2020

Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Oral amrinone in refractory congestive heart failure

1 reference

12 December 2020

Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent

1 reference

12 December 2020

Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle

1 reference

12 December 2020

Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals

1 reference

12 December 2020

Responses to Amrinone in Isolated Cardiac Muscles from Cat, Rabbit, and Guinea Pig

1 reference

12 December 2020

Amrinone and exercise performance in patients with chronic heart failure

1 reference

12 December 2020

Double-blind, randomised, cross-over comparison of oral captopril and enoximone added to diuretic treatment in patients with severe heart failure

1 reference

12 December 2020

Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart

1 reference

12 December 2020

Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium

1 reference

12 December 2020

Acute pharmacodynamics and pharmacokinetics of oral amrinone

1 reference

12 December 2020

Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients

1 reference

12 December 2020

Piroximone, dobutamine and nitroprusside: comparative effects on haemodynamics in patients with congestive heart failure

1 reference

12 December 2020

Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure

1 reference

12 December 2020

Clinical experience with amrinone in patients with advanced congestive heart failure

1 reference

12 December 2020

Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope

1 reference

12 December 2020

Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy

1 reference

12 December 2020

A dose-response study of intravenous enoximone in congestive heart failure

1 reference

12 December 2020

Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance

1 reference

12 December 2020

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

1 reference

12 December 2020

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside

1 reference

12 December 2020

Survival of patients with severe congestive heart failure treated with oral milrinone

1 reference

12 December 2020

Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure.

1 reference

12 December 2020

Role of Ca2+ channel in development of tension in heart muscle

1 reference

12 December 2020

New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

1 reference

12 December 2020

Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure

1 reference

12 December 2020

Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure

1 reference

12 December 2020

Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy

1 reference

12 December 2020

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

12 December 2020

MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.

1 reference

12 December 2020

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

12 December 2020

Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.

1 reference

12 December 2020

The electrophysiologic effects of enoximone in patients with preexisting ventricular tachyarrhythmias

1 reference

12 December 2020

Effects of long-term therapy with oral piroximone on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure

1 reference

12 December 2020

Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy

1 reference

12 December 2020

Long-term enoximone therapy in unstable chronic heart failure

1 reference

12 December 2020

The cardiotonic agent amrinone does not increase anatomic infarct size

1 reference

12 December 2020

Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effects of cardiotonic drugs

1 reference

12 December 2020

Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure

1 reference

12 December 2020

The role of novel inotropic agents in the treatment of heart failure

1 reference

12 December 2020

Comparative haemodynamic dose-response effects of dobutamine and amrinone in left ventricular failure complicating acute myocardial infarction.

1 reference

12 December 2020

Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility

1 reference

12 December 2020

Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise

1 reference

12 December 2020

Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure

1 reference

12 December 2020

Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol.

1 reference

12 December 2020

Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs

1 reference

12 December 2020

Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias

1 reference

12 December 2020

Pharmacology of the bipyridines: amrinone and milrinone.

1 reference

12 December 2020

Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure

1 reference

12 December 2020

Cardiovascular properties of a new cardiotonic agent, MDL 19205

1 reference

12 December 2020

Contractile proteins of the heart

1 reference

12 December 2020

[Determination of active components of amrinone by analysis of pressure-volume results; use of the conductance (volume) catheter technic and rapid load change by balloon occlusion of the inferior vena cava]

1 reference

12 December 2020

Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure

1 reference

12 December 2020

Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence.

1 reference

12 December 2020

Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure

1 reference

12 December 2020

Physiologic response to the inotropic and vasodilator properties of enoximone

1 reference

12 December 2020

Additive effects of enoximone and nitroprusside in unstable chronic heart failure

1 reference

12 December 2020

Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure

1 reference

12 December 2020

Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent

1 reference

12 December 2020

Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.

1 reference

12 December 2020

Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement

1 reference

12 December 2020

Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure

1 reference

12 December 2020

Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease

1 reference

12 December 2020

Combined hemodynamic and scintigraphic assessment of piroximone (MDL 19,205) and comparison with dobutamine and nitroprusside

1 reference

12 December 2020

MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response

1 reference

12 December 2020

Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: comparison with sodium nitroprusside

1 reference

12 December 2020

Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function

1 reference

12 December 2020

Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure

1 reference

12 December 2020

Hemodynamic and regional blood flow response to piroximone (MDL 19,205) in dogs with congestive heart failure: a comparison with dobutamine.

1 reference

12 December 2020

Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study

1 reference

12 December 2020

New cardiotonic agents: a search for digitalis substitute

1 reference

12 December 2020

Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial

1 reference

12 December 2020

LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.

1 reference

12 December 2020

Calcium and Cardiac Excitation-Contraction Coupling

1 reference

12 December 2020

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

1 reference

12 December 2020

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

1 reference

12 December 2020

Cardiotonic agents. 3. A topographical model of the cardiac cAMP phosphodiesterase receptor

1 reference

12 December 2020

Influence of enoximone on myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside

1 reference

12 December 2020

Effects of new inotropic agents on Ca++ sensitivity of contractile proteins

1 reference

12 December 2020

Side effects of amrinone therapy

1 reference

12 December 2020

Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment

1 reference

12 December 2020

Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease

1 reference

12 December 2020

Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone

1 reference

12 December 2020

Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure

1 reference

12 December 2020

Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure

1 reference

12 December 2020

Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy

1 reference

12 December 2020

Intravenous amrinone: an advance or a wrong step?

1 reference

12 December 2020

The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle

1 reference

12 December 2020

Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure

1 reference

12 December 2020

Intravenous use of enoximone.

1 reference

12 December 2020

Hemodynamic effects of prolonged intravenous therapy with enoximone in patients with severe congestive heart failure

1 reference

12 December 2020

Acute dose range study of milrinone in congestive heart failure.

1 reference

12 December 2020

Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.

1 reference

12 December 2020

Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.

1 reference

12 December 2020

Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure

1 reference

12 December 2020

Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure

1 reference

12 December 2020

Calcium ion and muscle contraction

1 reference

12 December 2020

Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis

1 reference

12 December 2020

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

12 December 2020

Reduced positive inotropic effects in diseased human ventricular myocardium

1 reference

12 December 2020

Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone

1 reference

12 December 2020

Electrophysiologic effects of enoximone in patients with congestive heart failure

1 reference

12 December 2020

Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Abnormal Intracellular Modulation of Calcium as a Major Cause of Cardiac Contractile Dysfunction

1 reference

12 December 2020

Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group

1 reference

12 December 2020

Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique

1 reference

12 December 2020

Enoximone. A review of its pharmacological properties and therapeutic potential

1 reference

12 December 2020

Oral treatment with enoximone in patients referred for cardiac transplantation.

1 reference

12 December 2020

Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systems

1 reference

12 December 2020

[Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison]

1 reference

12 December 2020

Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial

1 reference

12 December 2020

Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.

1 reference

12 December 2020

Distribution and regulation of the phosphodiesterases of muscle tissues

1 reference

12 December 2020

Amrinone in acute and long-term therapy

1 reference

12 December 2020

Excitation-contraction coupling in cardiac muscle

1 reference

12 December 2020

Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure

1 reference

12 December 2020

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

1 reference

12 December 2020

Long-term treatment with oral enoximone for chronic congestive heart failure: the European experience

1 reference

12 December 2020

Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.

1 reference

12 December 2020

Phosphodiesterase inhibition and positive inotropic effects.

1 reference

12 December 2020

Phosphodiesterase inhibitors and the cardiac sarcoplasmic reticulum calcium release channel: differential effects of milrinone and enoximone.

1 reference

12 December 2020

10.2165/00003495-199244060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference